Intravenous pamidronate increases bone density in postmenopausal women previously treated with oral bisphosphonates.

被引：0
|
作者：
Rastelli, A [1 ]
Napoli, N [1 ]
Civitelli, R [1 ]
机构：
[1] Washington Univ, Div Bone & Mineral Dis, St Louis, MO USA
来源：
JOURNAL OF BONE AND MINERAL RESEARCH | 2003年 / 18卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S159 / S159
页数：1
相关论文
共 50 条
  • [21] Early Effects of Denosumab in Postmenopausal Women with Low Bone Mineral Density Previously Treated with Alendronate
    Brown, J. P.
    Kendler, D. L.
    Benhamou, C. L.
    Lillestol, M.
    Roux, C.
    Siddhanti, S.
    Man, H. S.
    Martin, J. San
    Bone, H. G.
    ARTHRITIS AND RHEUMATISM, 2008, 58 (12): : 3973 - 3974
  • [22] Assessment of different markers of bone resorption in postmenopausal osteoporotic women treated with pamidronate
    Kollerup, G
    Sorensen, HA
    Hyldstrup, L
    Storm, T
    SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION, 1997, 57 (06): : 479 - 486
  • [23] Spinal bone mineral density in children and adolescents treated with cyclical intravenous pamidronate
    Elazabi, A.
    Adams, J. E.
    Mughal, M. Z.
    BONE, 2009, 45 : S104 - S104
  • [24] A single annual infusion is preferred to oral weekly treatment in postmenopausal women with low bone mineral density previously treated with alendronate.
    Omizo, M.
    McClung, M.
    Minkoff, J.
    Fiske, D.
    Kriegman, A.
    Davis, J.
    Zhou, W.
    JOURNAL OF BONE AND MINERAL RESEARCH, 2006, 21 : S289 - S289
  • [25] A single annual infusion is preferred to oral weekly treatment in postmenopausal women with low bone mineral density previously treated with alendronate.
    Omizo, M.
    McClung, M.
    Minkoff, J.
    Fiske, D.
    Kriegman, A.
    Davies, J.
    Zhou, W.
    ARTHRITIS AND RHEUMATISM, 2006, 54 (09): : S587 - S588
  • [26] Denosumab Leads To Significantly Greater Increases In Bone Mineral Density Than Ibandronate and Risedronate In Postmenopausal Women At High Risk For Fracture Who Were Previously Treated With An Oral Bisphosphonate
    Brown, Jacques P.
    Bolognese, Michael A.
    Ho, Pei-Ran
    Hall, Jesse
    Roux, Christian
    Bone, Henry G.
    Bonnick, Sydney
    van den Bergh, Joop
    Ferreira, Irene
    Ghelani, Prayashi
    Dakin, Paula
    Wagman, Rachel B.
    Recknor, Chris
    ARTHRITIS AND RHEUMATISM, 2013, 65 : S522 - S523
  • [27] Oral health and bone mineral density in postmenopausal women
    Grocholewicz, Katarzyna
    Bohatyrewicz, Andrzej
    ARCHIVES OF ORAL BIOLOGY, 2012, 57 (03) : 245 - 251
  • [28] BONE MINERAL DENSITY RESPONSE TO INTRAVENOUS PAMIDRONATE IN WOMEN WITH OSTEOPOROSIS - PRELIMINARY ANALYSIS
    Bianchet, Leila C.
    Marcatto, Cristina
    Kulak, Carolina A. M.
    Manas, Nadila C. R.
    Ramos, Cassio S.
    Borba, Victoria Z. C.
    OSTEOPOROSIS INTERNATIONAL, 2012, 23 : S356 - S356
  • [29] Intravenous pamidronate compared with oral alendronate for the treatment of postmenopausal osteoporosis
    Heijckmann, AC
    Juttmann, JR
    Wolffenbuttel, BHR
    NETHERLANDS JOURNAL OF MEDICINE, 2002, 60 (08): : 315 - 319
  • [30] Osteonecrosis of the jaws in patients with bone metastasis receiving intravenous bisphosphonates. A rising concern
    Bujanda D.A.
    Cabrera Suárez M.Á.
    Sarmiento U.B.
    Pérez S.Q.
    Morales J.A.
    Clinical and Translational Oncology, 2006, 8 (12) : 919 - 921
12345